[Updated status of VRTX entry for discontinuation of low-dose all-oral arm in phase-2 trial. I’m temporarily leaving the BMY entry pending information from AASLD and BMY’s 3Q10 CC.]
‡Low-dose all-oral arm discontinued (#msg-55917569). *All-oral trial has not started. †Program on clinical hold pending FDA review of SAE’s in drug-drug-interaction study.